Results 131 to 140 of about 44,548 (260)

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera

Blood Cancer Journal, 2021
Eliane Nguyen, Michaël Harnois, Lambert Busque, Shireen Sirhan, Sarit Assouline, Ines Chamaki, Harold Olney, Luigina Mollica, Natasha Szuber   +8 more
doaj   +1 more source

Neutralize the neutrophils! Neutrophil β1 /β2 integrin activation contributes to JAK2-V617F–driven thrombosis [PDF]

, 2018
Barbui, De Stefano, Sands, Stephen T. Oh, Wolach   +4 more
core   +2 more sources

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Mutations in cytokine receptor and JAK/STAT; Cy‐JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated the prevalence, clinical presentation, and prognostic significance of Cy‐JAK/STAT pathway mutations in patients with AML and ...
Moath Albliwi, Daniel P. Nurse, Emily C. Zabor, John Hanna, Jessica El‐Asmar, Ameed Bawwab, Hasan Abuamsha, Yomna Abu‐Farsakh, Heya Batah, Asad Rauf, Joy Nakitandwe, David S. Bosler, Prerana Bangalore Parthasarathy, Tyler Alban, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Moaath K. Mustafa Ali   +22 more
wiley   +1 more source

Adverse Prognostic Impact of Pretransplant Serum Ferritin and Hepcidin on Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation

American Journal of Hematology, Volume 101, Issue 6, Page 1239-1243, June 2026.
Michelle Pirotte, Marianne Fillet, Laurence Seidel, Evelyne Willems, Sophie Servais, Fréderic Baron, Yves Beguin   +6 more
wiley   +1 more source

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

HemaSphere, 2021
Hans C. Hasselbalch, Richard T. Silver
doaj   +1 more source

Associació de l'estat mutacional de JAK2 i les anomalies citogenètiques en les neoplàsies mieloproliferatives cròniques Filadèlfia negatives : Correlació amb les dades clíniques i analítiques [PDF]

, 2013
L'estudi correlaciona l'estat mutacional de JAK2V617F amb les alteracions citogenètiques, algunes dades clíniques i paràmetres de laboratori i valorar l'impacte sobre la progressió i pronòstic de la malaltia de 526 casos de NMPc Ph-.
Feliu Frasnedo, Evarist, Millá Santos, Fuensanta, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina, Xandri Puig, Marisol   +4 more
core  

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?

Haematologica, 2020
Richard T. Silver
doaj   +1 more source

MESENCHYMAL STEM CELLS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: IDLE OBSERVERS OR PART OF THE DISEASE? [PDF]

, 2019
Accurso, V., Cordova, A., Di Piazza, F., Di Stefano, A. B., Lo Re, J., Mancuso, S., Russo, A., Santoro, M., Siragusa, S.   +8 more
core   +1 more source

Single‐Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT‐035 Study

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non‐durable, and associated with cytopenias, underscoring the need for therapies with novel mechanisms of action.
Sebastian Grosicki, Habte Yimer, Rosa Ayala, Suning Chen, Hong Liu, Françoise Boyer, Paola Guglielmelli, Marco Brociner, Paolo Sportoletti, Gabor Mikala, Panagiotis Tsirigotis, Jin Zhang, Tomer Mark, Yi Chai, Andrea Ellero, Alessandro Lucchesi   +15 more
wiley   +1 more source